United Kingdom

UK First in Europe to Dispense Lilly's Weight-Loss Pill

Is the U.K.'s approval of orforglipron a medical breakthrough or a shortcut that will backfire?

Published AUG 24

UK First in Europe to Dispense Lilly's Weight-Loss Pill

Story

Above: Packaging for the Foundayo weight loss oral pill. Image credit: Michael Siluk/UCG/Universal Images Group/Getty Images

The Facts

Orforglipron, sold under the brand name Foundayo and manufactured by Eli Lilly, became available in U.K. pharmacies on Monday, making the country the first in Europe to approve and dispense the weight-loss pill.
Guardian
GB News
The Medicines and Healthcare products Regulatory Agency (MHRA) authorized the drug on Aug. 10 for adults with a BMI of 30 or above; a BMI of 27 to 30 with at least one weight-related condition; or to improve glycaemic control in poorly controlled type 2 diabetes.
GOV.UK
It is initially available only via private prescription in the U.K., while the National Institute for Health and Care Excellence (NICE), which expects to publish its guidance on Nov. 18, assesses the medication for a potential NHS rollout.
GOV.UK
Nice
Patients take the pill once daily at any time, without food or water restrictions. Dosage starts at 0.8 mg and escalates through five further stages to 17.2 mg, with a minimum of one month required at each dose level.
GOV.UK
Eli Lilly and Company
In the ATTAIN-1 Phase 3 clinical trial, participants taking the highest dose of Foundayo who remained on the treatment lost an average of 27.3 pounds, compared to 2.2 pounds for those on placebo, over 72 weeks.
Eli Lilly and Company
However, the medication comes with multiple potential side effects, including nausea, constipation, diarrhea, vomiting, abdominal pain and indigestion. The MHRA recommends that those who experience adverse effects report them to the Yellow Card scheme.
GOV.UK
Eli Lilly and Company

Sources Split

LEFT

CENTER

RIGHT

ESTAB
CRIT

CENTER

PRO
ESTAB

The Spin

Narrative A

The U.K.’s approval of orforglipron is a massive win for those struggling with obesity. This once-daily pill, with no food or water restrictions, has been proven to deliver nearly 12.5% weight loss in trials and finally gives patients a flexible, accessible option. This approval is a step in the right direction.

Eli Lilly and Company

GOV.UK

Narrative B

While obesity pills like orforglipron deliver real weight loss, they also bring real trade-offs, including more side effects, lean muscle loss and no proven quality-of-life gains at the one-year mark. Fundamentally, they fail to address the root causes driving obesity rates higher every decade: an unhealthy lifestyle, which only exercise, diet and environmental changes can fix.

NPR